Robert Anders

17PUBLICATIONS

222CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSolid tumoursPredictive and prognostic markersHaematological tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (17)

Sort by Publication Date:

|Jun 30, 2026

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

|Jan 12, 2026

A Randomized Phase II Study: CRS207/GVAX plus Anti-PD-1 and Anti-CTLA4 Recruits Mesothelin- and mKRAS-Specific T Cells into PDAC.

Katherine M Bever, Amanda L Huff, Ludmila Danilova

|Aug 15, 2025

Neoadjuvant Immunotherapy Promotes the Formation of Mature Tertiary Lymphoid Structures in a Remodeled Pancreatic Tumor Microenvironment.

Dimitrios N Sidiropoulos, Sarah M Shin, Meredith Wetzel

|May 23, 2025

A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic Adenocarcinoma.

Parul Agarwal, Matthew Guo, Kabeer Munjal

|May 19, 2025

Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal Cancer.

Eric S Christenson, Won Jin Ho, Daniel Shu

|Nov 21, 2024

Immune microenvironment of Epstein-Barr virus (EBV)-negative compared to EBV-associated gastric cancers: implications for immunotherapy.

Tracee L McMiller, Sepideh Besharati, Mark Yarchoan

Pageof 3

Frequent Collaborators

Elizabeth M Jaffee

Qingfeng Zhu

Won Jin Ho

Mark Yarchoan

Hao Wang

Elana J Fertig

Ludmila Danilova

Lei Zheng

Daniel Laheru

Jin He

Frequent Collaborators

Elizabeth M Jaffee

Qingfeng Zhu

Won Jin Ho

Mark Yarchoan